B.R.A.I.N. Biotechnology Research and Information Network AG (GB:0RFI)
LSE:0RFI
0RFI Stock Chart & Stats
€2.49
-€0.04(-1.13%)
At close: 4:00 PM EST
€2.49
-€0.04(-1.13%)
Day’s Range― - ―
52-Week Range€1.81 - €3.90
Previous CloseN/A
Volume57.99K
Average Volume (3M)6.32K
Market Cap
€60.08M
Enterprise Value€64.57M
Total Cash (Recent Filing)€6.32M
Total Debt (Recent Filing)€24.03M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding21,847,494
10 Day Avg. Volume6,862
30 Day Avg. Volume6,320
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€55.79M
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn improving gross margin signals better cost control or a more favorable product mix. If sustained, higher gross margins create structural room to invest in R&D or absorb operating costs, supporting a path toward profitability even while operating losses persist.
Free Cash Flow ImprovementA reduction in negative free cash flow, even from a negative base, reduces near-term external funding pressure. Continued improvement would lengthen the company’s runway, lowering refinancing frequency and giving management more flexibility to execute strategic R&D and commercialization steps.
Established WorkforceA near-300-person workforce indicates retained operational and scientific capacity, supporting ongoing R&D and regulatory work. Maintaining skilled staff is a durable asset for biotech firms, preserving institutional knowledge and the ability to advance pipelines over multiple quarters.
Bears Say
Persistent Net LossesOngoing net losses and continued cash burn are structural headwinds that erode equity and force repeated capital raises. Persistent unprofitability undermines long-term viability unless offset by clear progress toward commercial revenue or sustained margin expansion.
Declining RevenueConsecutive years of revenue decline indicate weakening top-line momentum and reduce leverage of fixed R&D and G&A spend. Without reversing revenue trends, the company faces tougher trade-offs between funding growth, preserving cash, and avoiding further dilution.
Heightened Balance-sheet LeverageA steep drop in equity and higher debt-to-equity increases refinancing and dilution risk. Elevated leverage reduces financial flexibility, raises funding costs, and can constrain the company’s ability to fund trials or commercialization without materially dilutive raises or costly borrowing.
0RFI FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest share price was €1.81 and its highest was €3.90 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €60.08M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Aug 27, 2026 which is in 77 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on May 28, 2026. The company reported -€0.29 earnings per share for the quarter, missing the consensus estimate of -€0.09 by -€0.2.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.29 in its last earnings report, missing expectations of -€0.09. Following the earnings report the stock price went up 2.74%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in GB:0RFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-1361.43%
Trailing 12-Months
Asset Growth
-25.24%
Trailing 12-Months
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.